Phase II clinical development of new drugs

This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful exec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ting, Naitee, Chen, Ding-Geng, Ho, Shuyen, Cappelleri, Joseph C
Lenguaje:eng
Publicado: Springer 2017
Materias:
Mathematical Physics and Mathematics
Acceso en línea:https://dx.doi.org/10.1007/978-981-10-4194-5
http://cds.cern.ch/record/2263533
_version_ 1780954241349713920
author Ting, Naitee
Chen, Ding-Geng
Ho, Shuyen
Cappelleri, Joseph C
author_facet Ting, Naitee
Chen, Ding-Geng
Ho, Shuyen
Cappelleri, Joseph C
author_sort Ting, Naitee
collection CERN
description This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them.
id cern-2263533
institution Organización Europea para la Investigación Nuclear
language eng
publishDate 2017
publisher Springer
record_format invenio
spelling cern-22635332021-04-21T19:14:32Zdoi:10.1007/978-981-10-4194-5http://cds.cern.ch/record/2263533engTing, NaiteeChen, Ding-GengHo, ShuyenCappelleri, Joseph CPhase II clinical development of new drugsMathematical Physics and MathematicsThis book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them.Springeroai:cds.cern.ch:22635332017
spellingShingle Mathematical Physics and Mathematics
Ting, Naitee
Chen, Ding-Geng
Ho, Shuyen
Cappelleri, Joseph C
Phase II clinical development of new drugs
title Phase II clinical development of new drugs
title_full Phase II clinical development of new drugs
title_fullStr Phase II clinical development of new drugs
title_full_unstemmed Phase II clinical development of new drugs
title_short Phase II clinical development of new drugs
title_sort phase ii clinical development of new drugs
topic Mathematical Physics and Mathematics
url https://dx.doi.org/10.1007/978-981-10-4194-5
http://cds.cern.ch/record/2263533
work_keys_str_mv AT tingnaitee phaseiiclinicaldevelopmentofnewdrugs
AT chendinggeng phaseiiclinicaldevelopmentofnewdrugs
AT hoshuyen phaseiiclinicaldevelopmentofnewdrugs
AT cappellerijosephc phaseiiclinicaldevelopmentofnewdrugs

Ejemplares similares